Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
- 18 January 2022
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 163, 98-107
- https://doi.org/10.1016/j.ejca.2021.11.017
Abstract
No abstract availableFunding Information
- AbbVie
- Bristol-Myers Squibb
- Sanofi
This publication has 33 references indexed in Scilit:
- Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation ofIDHJournal of Clinical Oncology, 2014
- The Somatic Genomic Landscape of GlioblastomaCell, 2013
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951Journal of Clinical Oncology, 2013
- Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic FactorsJournal of Clinical Oncology, 2012
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomasThe Lancet Oncology, 2011
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytomaActa Neuropathologica, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I TrialsJournal of Clinical Oncology, 2009
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysisNeuro-Oncology, 2004